

MONOPAR THERAPEUTICS

Reported by CITTADINE ANDREW

FORM 4

(Statement of Changes in Beneficial Ownership)

Filed 04/02/25 for the Period Ending 03/31/25

Address 1000 SKOKIE BLVD SUITE 350

WILMETTE, IL, 60091

Telephone 8473880349

CIK 0001645469

Symbol MNPR

SIC Code 2834 - Pharmaceutical Preparations

Industry Biotechnology & Medical Research

Sector Healthcare

Fiscal Year 12/31



FORM 4

☐ Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. *See* Instruction 1(b).

☐ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person *					2. Issuer Name and Ticker or Trading Symbol							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
Cittadine Andrew				Mo	Monopar Therapeutics [MNPR]						Director	,	100/	O		
(Last) (First) (Middle)				3. D	3. Date of Earliest Transaction (MM/DD/YYYY)						X Officer (gir	ve title belov		Owner her (specify)	helow)	
1000 SKOKIE BLVD SUITE 350					3/31/2025						**	Chief Operating Officer				
(Street)				4. I1	4. If Amendment, Date Original Filed (MM/DD/YYYY)						6. Individual o	6. Individual or Joint/Group Filing (Check Applicable Line)				
WILMETTE, IL 60091											X_Form filed by One Reporting Person Form filed by More than One Reporting Person					
(C	ity) (Sta	te) (Zip)	l									Form filed by	More man C	nie Keporting F	erson	
		r ·	Гable <u>I</u> - N	Non-Deri	ivativ	ve Seci	urities Acc	quire	ed, Di	sposed o	of, or Be	neficially Owne	d			
1. Title of Security (Instr. 3)				ate 2A. Deemed Execution Date, if any		3. Trans. Co (Instr. 8)	de	or Disposed of (D)		Following Reported Transaction(s) Instr. 3 and 4)			6. 7. Nature Ownership Form: Beneficial Direct (D) or Indirect (Instr. 4)			
							Code	V	Amou	(A) or (D)	Price				(I) (Instr. 4)	(
Common Stock 3/31/202				31/2025			M		1,79		<u>(1)</u>			42,729	D	
Common Stock			3/3	31/2025			F		744	<u>2)</u> D	\$36.41			41,985	D	
	Tab	le II - Deri	vative Sec	curities E	Benef	ficially	Owned (e.g.,	puts,	calls, wa	arrants,	options, conver	tible secu	ırities)		
Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	rsion Date Execution Date of tive	3A. Deemed Execution Date, if any	Code	tr. 8) Derivat Acquir Dispos		per of we Securities d (A) or d of (D) 4 and 5)		ite Exer Expiration		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		Derivative Security (Instr. 5)		Ownership Form of Derivative	Beneficial
	Security			Code	V	(A)	(D)	Date Exerc	cisable	Expiration Date	Title	Amount or Number of Shares		Reported Transaction(s) (Instr. 4)	or Indirect	
Restricted Stock Units	(1)	3/31/2024		M			1,791	(3	<u>8)(4)</u>	(3)(4)	Commo Stock	on 1,791	\$0	49,864	D	

Explanation of Responses:

- (1) Represents shares acquired on vesting and settlement of restricted stock units.
- (2) Represents shares withheld by the issuer to pay for the applicable withholding tax due upon vesting of restricted stock units.
- (3) On February 2, 2022, the reporting person was granted 13,000 restricted stock units, vesting 6/48ths (1,625 shares) on June 30, 2022, and 3/48ths (813 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2025. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.
- (4) On February 1, 2023, the reporting person was granted 15,647 restricted stock units, vesting 6/48ths (1,956 shares) on June 30, 2023, and 3/48ths (978 shares) every 3 months thereafter until the RSU is fully vested on December 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

Reporting Owners

Demonting Oxymon Name / Address	Relationships						
Reporting Owner Name / Address	Director	10% Owner	Officer	Other			
Cittadine Andrew							
1000 SKOKIE BLVD SUITE 350			Chief Operating Officer				

WILMETTE, IL 60091			
Signatures		•	

/s/ Quan Vu, Attorney-in-fact

**Signature of Reporting Person

4/2/2025 Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.